铜(II)-双(硫脲基)配合物:一种用于检测神经退行性疾病中氧化应激和神经炎症的潜在放射性示踪剂
本文综述铜(II)-双(缩氨基硫脲)配合物尤其是Cu-ATSM作为诊疗一体化放射性药物在神经退行性疾病中的应用。临床研究显示帕金森病、阿尔茨海默病和肌萎缩侧索硬化患者中⁶⁴Cu-ATSM摄取升高,与疾病严重程度和区域氧化应激标志物相关。作者指出小队列规模和临床研究异质性等局限,认为需更大规模验证。
要点
- Cu-ATSM在病理微环境中呈氧化还原依赖性滞留,可用于PET无创检测氧化应激。
- 临床研究显示帕金森病、阿尔茨海默病和肌萎缩侧索硬化患者中⁶⁴Cu-ATSM摄取升高,与疾病严重程度相关。
- 作者指出小队列规模和临床研究异质性等局限,认为需更大规模验证。
核心结论
- Cu-ATSM是阐明神经病理机制和推进神经退行性疾病治疗策略的变革性工具。
研究设计与样本
- 本文为综述,探讨铜(II)-双(缩氨基硫脲)配合物尤其是Cu-ATSM作为诊疗一体化放射性药物的潜力。
主要发现
- 临床研究显示帕金森病、阿尔茨海默病和肌萎缩侧索硬化患者中⁶⁴Cu-ATSM摄取升高,与疾病严重程度和区域氧化应激标志物相关。
- 临床前研究显示Cu-ATSM通过抑制胶质激活、减少促炎细胞因子(如TNF-α、MCP-1)分泌和增加神经保护性金属硫蛋白-1(MT1)表达来减轻神经炎症。
- Cu-ATSM衍生物在肌萎缩侧索硬化模型中显示出调节血脑屏障通透性、增强淀粉样蛋白β清除和恢复铜稳态的前景。
临床怎么用
- 原文未据此给出推荐。
局限性
- 小队列规模和临床研究异质性等局限,作者认为需更大规模验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Neurodegenerative diseases, characterized by progressive neuronal degeneration and associated with neuroinflammation and oxidative stress, present significant challenges in diagnosis and treatment. This review explores the potential of copper(II)-bis(thiosemicarbazone) complexes, particularly Cu-ATSM, as a dual-purpose radiopharmaceutical for imaging and therapeutic interventions. Cu-ATSM exhibits unique redox-dependent retention in pathological microenvironments, driven by mitochondrial dysfunction and hyper-reductive states, which enables the noninvasive detection of oxidative stress via positron emission tomography (PET). Preclinical studies demonstrate its efficacy in mitigating neuroinflammation by suppressing glial activation, reducing the secretion of pro-inflammatory cytokines (e.g., TNF-α, MCP-1), and increasing the expression of neuroprotective metallothionein-1 (MT1). Some Clinical research reveals elevated ⁶⁴Cu-ATSM uptake in Parkinson's disease (PD), Alzheimer's disease (AD), and amyotrophic lateral sclerosis (ALS) patients, correlating with disease severity and regional oxidative stress markers. Furthermore, Cu-ATSM derivatives show promise in modulating blood-brain barrier (BBB) permeability, enhancing amyloid-β clearance, and restoring copper homeostasis in ALS models. Despite these advances, limitations such as small cohort sizes and heterogeneity in clinical studies underscore the need for larger-scale validation. Multimodal imaging integrating PET and MRI, alongside novel structural analogs targeting Aβ plaques and redox imbalances, emerges as a strategic direction for future research. Collectively, Cu-ATSM represents a transformative tool for elucidating neuropathological mechanisms and advancing therapeutic strategies in neurodegenerative disorders.
引用
- Lin W, Huang C, Tan Z, et al. CuII-bis(thioureido) Complex: A Potential Radiotracer for Detecting Oxidative Stress and Neuroinflammation in Neurodegenerative Diseases. Semin Nucl Med. 2025. PMID: 40360341. doi:10.1053/j.semnuclmed.2025.03.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。